Arriving in the landscape of excess body fat treatment, retatrutide represents a different strategy. Different from many available medications, retatrutide functions as a double agonist, concurrently engaging both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) binding sites. The dual engagement encourages vario